BMY News & Events

Catch up on the weekend's top five stories with this list compiled by The Fly: 1) Colorado Attorney General Phil Weiser announced on X Friday night that the judge in the state's case challenging the Nexstar (NXST) - Tegna merger issued a temporary restraining order, blocking the companies from merging. On April 7, the judge will consider the request to bar the merger "while we make our case to stop it permanently," Weiser added. U.S. District Judge Troy Nunley sided with DirecTV, which claimed that Nexstar's acquisition of Tegna would "drive up the price it can extract from DirecTV and other distributors," bring layoffs and reduce competition. DirecTV established "a likelihood of success on the merits" on its claim, and that moving forward with the transaction would create "irreparable harm," the judge wrote. Eight states sued to block the merger in a separate filing on the same day as DirecTV's. 2) Insilico Medicine announced a drug discovery collaboration with Eli Lilly and Company (LLY) that uses Insilico's AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas. The agreement grants Lilly an exclusive worldwide license for the development, manufacturing, and commercialization of potentially best-in-class, novel oral therapeutics in preclinical development for certain indications. In addition, Insilico and Lilly will collaborate on multiple R&D programs focused on targets selected by Lilly, by combining Insilico's state-of-the-art Pharma.AI platforms with Lilly's development capabilities and deep disease-area expertise. Under the terms of the agreement, Insilico is eligible to receive an $115 million upfront payment, followed by development, regulatory, and commercial milestones that could bring the total deal value to approximately $2.75 billion, plus tiered royalties on future sales. 3) Bristol Myers Squibb (BMY) announced positive data from the Phase 3 Scout-HCM trial of Camzyos, the first study of a cardiac myosin inhibitor in adolescents with symptomatic obstructive hypertrophic cardiomyopathy. The Scout-HCM trial met its primary endpoint, demonstrating a clinically meaningful and statistically significant reduction from baseline in Valsalva left ventricular outflow tract gradient at Week 28 with Camzyos versus placebo. 4) Eli Lilly and Company announced detailed results from the Together-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz and Zepbound compared to Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one additional weight-related comorbid condition. At the primary endpoint of 36 weeks, treatment with concomitant Taltz and Zepbound met the primary and all key secondary endpoints for statistically significant superiority to Taltz monotherapy. 5) Boston Scientific (BSX) announced that the Champion-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the Watchman FLX Left Atrial Appendage Closure, LAAC, Device compared to non-vitamin K antagonist oral anticoagulants, NOACs, as a first-line option for stroke risk reduction in a broad population of patients with non-valvular atrial fibrillation, NVAF. At 36 months: The primary safety endpoint was met with data demonstrating the WATCHMAN FLX device was statistically superior to NOACs for non-procedural major and clinically relevant non-major bleeding, achieving a 45% relative reduction in non-procedural bleeding risk.

Bristol Myers Squibb announced positive data from the Phase 3 Scout-HCM trial of Camzyos, the first study of a cardiac myosin inhibitor in adolescents with symptomatic obstructive hypertrophic cardiomyopathy. The Scout-HCM trial met its primary endpoint, demonstrating a clinically meaningful and statistically significant reduction from baseline in Valsalva left ventricular outflow tract gradient at Week 28 with Camzyos versus placebo. Additionally, Camzyos showed meaningful improvement over placebo in multiple secondary endpoints at 28 weeks, and similar safety findings were observed in the Camzyos and placebo groups. The data are being presented as a late-breaking clinical trial presentation at the American College of Cardiology's, ACC, Annual Scientific Session & Expo 2026, with simultaneous publication in The New England Journal of Medicine. Scout-HCM evaluated Camzyos compared to placebo in 44 patients aged 12 to less than 18 years old with symptomatic oHCM and New York Heart Association class II-III symptoms over a 28-week period. In addition to meeting the primary endpoint of reduction of Valsalva LVOT gradient, Camzyos showed meaningful improvements over placebo in LV obstruction, diastolic function, maximal left ventricular wall thickness, NYHA class, and mitral valve dysfunction at 28 weeks.

Bristol Myers Squibb announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy when switching adult outpatients with schizophrenia from an oral atypical antipsychotic to Cobenfy monotherapy. Through 8 weeks, patients remained stable with mean Positive and Negative Syndrome Scale, PANSS, total scores remaining below baseline, and no new safety signals were observed, regardless of cross-titration duration. Data were presented at the 2026 Annual Congress of the Schizophrenia International Research Society, SIRS, taking place March 25-29 in Florence, Italy. The primary objective of the trial was to evaluate the rate of all-cause Cobenfy discontinuation over a period of 8 weeks. Key secondary endpoints included Cobenfy discontinuation due to a lack of efficacy, incidence of, and discontinuations due to adverse events, change from baseline to week 8 in the PANSS total score, CGI-S, Personal and Social Performance, and Medication Satisfaction Questionnaire. In the trial, approximately 86% of patients completed 8 weeks of treatment, with discontinuation rates of 15.1% and 13.5% in the slower and faster transition groups. No patients discontinued treatment with Cobenfy due to lack of efficacy. Mean changes in PANSS total scores from baseline to week 8 were -4.2 in the slower transition group and -3.1 in the faster transition group. Mean change in CGI-S scores was -0.2 in both the slower and faster transition groups. From baseline to week 8, mean PSP scores improved by 1.1 and 0.7 in the slower and faster transition groups, respectively.